Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.94 USD | -0.29% | +10.01% | -20.74% |
May. 31 | Ionis Reports 'Positive Results' From Studies of Investigational Treatment for Hereditary Angioedema | MT |
May. 31 | Transcript : Ionis Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.74% | 5.84B | |
+53.85% | 55.7B | |
+41.08% | 39.91B | |
-5.79% | 39.57B | |
-5.56% | 28.16B | |
+16.43% | 26.3B | |
-20.24% | 18.94B | |
+32.87% | 12.17B | |
+26.88% | 12.12B | |
+2.18% | 12.12B |
- Stock Market
- Equities
- IONS Stock
- News Ionis Pharmaceuticals, Inc.
- Piper Sandler Adjusts Ionis Pharmaceuticals' Price Target to $62 From $60, Maintains Overweight Rating